Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07102459
PHASE2

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

Sponsor: Latigo Biotherapeutics

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical abdominoplasty over 48 hours? How tolerable is LTG-001 over 48 hours? What dose of LTG-001 is better for treating post-operative / acute pain? Participants will: Take LTG-001 bid after the surgical abdominoplasty. Remain at the clinic for approximately 48 hours during study dosing and return after two weeks for a safety check up. Report the pain relief during the 48 hours to record changes in the post-operative pain.

Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After an Abdominoplasty

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

343

Start Date

2025-07-24

Completion Date

2026-01-07

Last Updated

2026-04-29

Healthy Volunteers

No

Interventions

DRUG

Experimental: LTG-001 High Dose

High Dose Active

DRUG

Experimental: LTG-001 Low Dose

Lower Dose Active

DRUG

Active Comparator: HB/APAP

Active Comparator

DRUG

Placebo Comparator

Placebo

Locations (5)

Arizona Research Center

Phoenix, Arizona, United States

CenExel ACMR

Atlanta, Georgia, United States

HD Research LLC

Houston, Texas, United States

Endeavor Clinical Research

San Antonio, Texas, United States

JBR Clinical Research (CenExel)

Salt Lake City, Utah, United States